Purple Biotech director reports 3.09M share stake
PURPLE BIOTECH LTD. director Agmon Ido filed an initial ownership report showing substantial equity exposure.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
PURPLE BIOTECH LTD. director Agmon Ido filed an initial ownership report showing substantial equity exposure. He beneficially owns 3,093,860 Ordinary Shares, including 2,454,167 unvested RSUs that settle in Ordinary Shares, and holds stock options over an additional 2,950,000 Ordinary Shares at low exercise prices.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Agmon Ido
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,950,000 contracts (Direct);
Ordinary Shares — 3,093,860 shares (Direct)
Footnotes (3)
- F1. Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares
- F2. Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24, 2026. The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028.
- F3. Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.
Key Figures
Beneficially owned Ordinary Shares: 3,093,860 shares
Unvested RSUs: 2,454,167 units
Option 1 underlying shares: 300,000 shares
+4 more
7 metrics
Beneficially owned Ordinary Shares
3,093,860 shares
Initial ownership reported by director Agmon Ido
Unvested RSUs
2,454,167 units
Each RSU represents one Ordinary Share
Option 1 underlying shares
300,000 shares
Stock option under 2016 Equity-Based Incentive Plan
Option 1 exercise price
$0.059375 per share
Expires April 24, 2028
Option 2 underlying shares
2,650,000 shares
Stock option under 2016 Equity-Based Incentive Plan
Option 2 exercise price
$0.00309375 per share
Expires October 21, 2030
ADS ratio
1 ADS : 2,000 Ordinary Shares
Representation of Ordinary Shares by ADSs
Key Terms
restricted stock units ("RSUs"), American Depositary Shares, Equity-Based Incentive Plan, vested and exercisable, +1 more
5 terms
restricted stock units ("RSUs") financial
"Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Equity-Based Incentive Plan financial
"issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan"
vested and exercisable financial
"Options to purchase 274,997 Ordinary Shares are vested and exercisable"
time-based vesting conditions financial
"The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 filing by Agmon Ido at PPBT show?
The Form 3 shows director Agmon Ido’s initial ownership in Purple Biotech. He reports 3,093,860 Ordinary Shares beneficially owned, plus stock options over 2,950,000 additional shares, giving investors a view of his total equity-based position in the company.
How many RSUs does Agmon Ido hold in Purple Biotech (PPBT)?
Agmon Ido holds 2,454,167 unvested RSUs, each representing one Ordinary Share of Purple Biotech. These RSUs vest over time based on service conditions and are settled in Ordinary Shares, aligning his compensation with the company’s long-term performance.
What stock options does Agmon Ido have in PPBT and at what prices?
He has stock options to purchase 300,000 Ordinary Shares at $0.059375 per share and 2,650,000 Ordinary Shares at $0.00309375 per share. These options were granted under Purple Biotech’s 2016 Equity-Based Incentive Plan and have multi-year expiration dates.
When do Agmon Ido’s Purple Biotech (PPBT) options vest and expire?
Options for 300,000 shares have 274,997 shares vested, with 25,003 vesting quarterly until April 24, 2026 and expiring April 24, 2028. Options for 2,650,000 shares vest quarterly until October 21, 2028 and expire on October 21, 2030.
AI-generated analysis. How Rhea-AI works. Not financial advice.
